Furthermore, MAP17 ectopic expression induces increased sensitivity to the treatment with certain ROS-inducing drugs.41,42,45 Nevertheless, higher MAP17 levels, in sarcoma patients, are prognostic of poor survival.41 The seemingly opposite properties of poor survival and increased sensitivity to certain treatments of MAP17 turn this protein into a suitable biomarker to improve the treatment and survival of certain patients with a specific molecular signature. This evidence concerns the gene PDZK1IP1 and sarcoma.